Talic, Stella
Marquina, Clara
Ofori-Asenso, Richard
Petrova, Marjana
Liew, Danny
Owen, Alice J.
Lybrand, Sean
Thomson, David
Ilomaki, Jenni
Zomer, Ella
Ademi, Zanfina http://orcid.org/0000-0002-0625-3522
Funding for this research was provided by:
Amgen Australia (Amgen Australia Pty Ltd has provided financial support to Monash University for analyses that describe the current burden and treatment of CVD in Australia, of which this manuscript forms a part.)
Article History
Accepted: 6 May 2021
First Online: 7 June 2021
Conflict of Interest
: ROA declares no conflict of interest. Authors ZA, EZ, ST, CM, MP, AO and DL have received research funding from Amgen Australia Pty Ltd. underlying this manuscript. JI has received funding from AstraZeneca, Amgen, Dementia Australia, National Breast Cancer Foundation and National Health and Medical Research Council. DT is employed by Amgen Australia Pty Ltd., and SL was employed by Amgen Australia Pty Ltd. at the time of development of the research and is now employed by Amgen Europe GmbH. EZ reports grant support from Amgen, AstraZeneca, Pfizer, and Shire, outside the submitted work. DL declares grants from Abbvie, Amgen, AstraZeneca, Bristol-Myers Squibb, Pfizer and Sanofi, and past participation in advisory boards and/or receipt of honoraria from Abbvie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Edwards Lifesciences, Novartis, Pfizer, Sanofi and Shire, outside the submitted work.